ASCO Genitourinary Symposium

Women May Experience Worse Quality of Life Than Men After Bladder Cancer Surgery

February 22nd 2023, 2:00pm

Article

Important data may encourage gender-specific treatment making decisions for patients with bladder cancer.

Ointment Being Studied for Hand-Foot Skin Reaction Related to Kidney Cancer Treatment

February 21st 2023, 10:00pm

Article

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

Survival Is Not Improved by Adding Tecentriq to Chemo for Metastatic Bladder Cancer

February 20th 2023, 4:00pm

Article

The addition of Tecentriq to platinum-based chemotherapy/gemcitabine did not boost outcomes in patients with metastatic bladder cancer, according to results from the IMvigor 140 trial.

Adding Cabometyx to Immunotherapy Improves Kidney Cancer Outcomes

February 20th 2023, 2:04pm

Article

The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.

Biomarkers May Predict Outcomes With Padcev to Treat Bladder Cancer Subtype

February 19th 2023, 7:00pm

Article

Researchers identified several biomarkers that may indicate how a patient responds to Padcev, a type of antibody drug conjugate for patients with urothelial carcinoma, a type of bladder cancer.

Nubeqa, ADT Combo Should Be New Standard of Care for Some Patients With Prostate Cancer

February 18th 2023, 4:00pm

Article

The combination demonstrated survival benefit in patients with metastatic hormone-sensitive prostate cancer, regardless of risk or volume of disease.

Treatment With Pluvicto Soon After Radium-223 Is Safe, Effective for Prostate Cancer

February 17th 2023, 2:00pm

Article

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed.

Nubeqa Outperforms Xtandi, Erleada in Non-metastatic Castration-resistant Prostate Cancer

February 16th 2023, 10:00pm

Article

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.

PSMA-Targeted Treatment Improves Bone-Related Pain in Metastatic, Castration-Resistant Prostate Cancer

March 7th 2022, 4:00pm

Article

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

Drug Duo Sparks Encouraging Outcomes in Treatment of Clear Cell Kidney Cancer

March 1st 2022, 10:00pm

Article

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.